HealthQuill PSD prevalence
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Medical

High rates of depression among stroke survivors over long periods: Study

HQ Team April 17, 2024: A recent study published in The Lancet Regional Health: Europe has found that nearly 60 percent of stroke.

Read More
X